Enhanced absorption of modified release dosage forms
Disclosed are products and methods for improving the plasma profile in a patient being treated with a pharmaceutical active agent that is subject to a limited window of absorption, which products and methods comprise orally administering the active agent in multiparticulate form, such that at least a portion thereof is delivered to the intestine while the patient is in the fed condition.
1 . A method for treating a patient comprising: treating a patient in the fed state with a pharmaceutical product, said pharmaceutical product comprising a modified release dosage form including a pharmaceutically active agent, said pharmaceutically active agent having a limited window of absorption, said modified release dosage form being a dosage form that is released from the stomach into the intestine as particulates, said particulates releasing at least a portion of the pharmaceutically active agent in the small intestine.
2 . The method of claim 1 , wherein said active agent exhibits a limited window of absorption of 6-8 hours or less.
3 . The method of claim 1 , wherein said active agent exhibits a limited window of absorption of 2-3 hours or less.
4 . The method of claim 1 , wherein said pharmaceutical product is in the form of a capsule.
5 . The method of claim 1 , wherein said pharmaceutical product is in the form of a suspension.
6 . The method of claim 1 , wherein said pharmaceutical product is in the form of a sprinkle pharmaceutical product.
7 . The method of claim 1 , wherein said pharmaceutical product is a rapidly disintegrating tablet.
8 . The method of claim 1 , wherein said pharmaceutical product is a delayed disintegrating tablet.
9 . The method of claim 1 , wherein said pharmaceutically active agent is amoxicillin.
10 . The method of claim 1 , wherein said pharmaceutically active agent is ciprofloxacin.
11 . The method of claim 1 , wherein said pharmaceutically active agent is cephalexin.
12 . The method of claim 1 , wherein said treating a patient in the fed state with a pharmaceutical product is a once-a-day treating of said patient.
13 . A product for treating a patient comprising: (a) a pharmaceutical product comprising a modified release dosage form including a pharmaceutically active agent, said pharmaceutically active agent having a limited window of absorption, said modified release dosage form being a dosage form that is released from the stomach into the intestine as particulates, said particulates releasing at least a portion of the pharmaceutically active agent in the small intestine, and (b) and instructions directing that the pharmaceutical product is to be administered to said patient while said patient is in the fed condition.
14 . The product of claim 13 , wherein said active agent exhibits a limited window of absorption of 6-8 hours or less.
15 . The product of claim 13 , wherein said active agent exhibits a limited window of absorption of 2-3 hours or less.
16 . The product of claim 13 , wherein said pharmaceutical product is in the form of a capsule.
17 . The product of claim 13 , wherein said pharmaceutical product is in the form of a suspension.
18 . The product of claim 13 , wherein said pharmaceutical product is in the form of a sprinkle pharmaceutical product.
19 . The product of claim 13 , wherein said pharmaceutical product is a rapidly disintegrating tablet.
20 . The product of claim 13 , wherein said pharmaceutical product is a delayed disintegrating tablet.
21 . The product of claim 13 , wherein said active agent is amoxicillin.
22 . The product of claim 13 , wherein said active agent is ciprofloxacin.
23 . The product of claim 13 , wherein said active agent is cephalexin.
24 . The product of claim 13 , wherein said pharmaceutical product is a once-a-day pharmaceutical product.